ASX:Live
Short Term
Mean Reversion
Neutral
Trend
Neutral
Event
Neutral
Halo Model
MQV
Very Weak
GARP
Very Weak
MQV Small
Neutral
Valuation
Value
Consensus
Momentum
Price
Very Strong
Earnings
Very Weak
Growth
Earnings
Very Weak
Dividends
Very Weak
Quality
Capital Efficiency
Very Weak
Balance Sheet
Very Weak
Website
N/A
Telephone
61.13.0099.5098
Address
Unit 2.06 31 Lexington Drive Bella Vista, New South Wales (NSW) 2153
Description
Cambium Bio Ltd. engages in the development and commercialization of regenerative therapies derived from novel processed human platelets. The company is headquartered in Paddington, Australia.
Market Cap
PE
EV/EBITDA
DIV Yield
Franking
Ex Dividend Date (est.)
52 weeks range
Low 0.19 - 0.68
Trade Value (12mth)
AU$995.00
1 week
-0.97%
1 month
37.84%
YTD
20%
1 year
70%
All time high
64.51
EPS 3 yr Growth
-85.10%
EBITDA Margin
-640.30%
Operating Cashflow
-$5m
Free Cash Flow Return
-199.80%
ROIC
-146.60%
Interest Coverage
-122.70
Quick Ratio
0.40
Shares on Issue (Fully Dilluted)
18m
HALO Sector
Healthcare
Next Company Report Date
28-Aug-26
Ex Dividend Date (est.)
N/A
Next Dividend Pay Date (est.)
N/A
Reporting Currency
AUD
Short Sell (% of issue)
0.00
| Date | Announcements |
|---|---|
|
05 September 25 |
Cambium Bio Signs Strategic MoU with Benta SAS
×
Cambium Bio Signs Strategic MoU with Benta SAS |
|
02 September 25 |
Cambium Bio Signs US$2.0M plus Licensing Deal
×
Cambium Bio Signs US$2.0M plus Licensing Deal |
|
29 August 25 |
FY25 Appendix 4G and Corporate Governance Statement
×
FY25 Appendix 4G and Corporate Governance Statement |
|
29 August 25 |
FY25 Appendix 4E and Annual Report
×
FY25 Appendix 4E and Annual Report |
|
29 August 25 |
Cleansing notice
×
Cleansing notice |
|
29 August 25 |
Application for quotation of securities - CMB
×
Application for quotation of securities - CMB |
|
27 August 25 |
Update - Proposed issue of securities - CMB
×
Update - Proposed issue of securities - CMB |
|
27 August 25 |
Placement Participant Update
×
Placement Participant Update |
|
31 July 25 |
Quarterly Activities/Appendix 4C Cash Flow Report
×
Quarterly Activities/Appendix 4C Cash Flow Report |
|
30 July 25 |
Proposed issue of securities - CMB
×
Proposed issue of securities - CMB |
|
30 July 25 |
Cambium Bio Raises A$2.12 million
×
Cambium Bio Raises A$2.12 million |
|
11 July 25 |
Cambium Bio Clears FDA Regulatory Hurdles
×
Cambium Bio Clears FDA Regulatory Hurdles |
|
30 June 25 |
Cambium Bio Receives Ethics Approvals
×
Cambium Bio Receives Ethics Approvals |
|
23 May 25 |
Change of Address
×
Change of Address |
|
22 May 25 |
Initial Director's Interest Notice - Denese Marks
×
Initial Director's Interest Notice - Denese Marks |
|
22 May 25 |
Final Director's Interest Notice - Barry Sechos
×
Final Director's Interest Notice - Barry Sechos |
|
21 May 25 |
Board and Company Secretary Changes
×
Board and Company Secretary Changes |
|
28 April 25 |
Quarterly Activities/Appendix 4C Cash Flow Report
×
Quarterly Activities/Appendix 4C Cash Flow Report |
|
14 April 25 |
Change of registry address
×
Change of registry address |
|
11 April 25 |
Notice of ceasing to be a substantial holder
×
Notice of ceasing to be a substantial holder |
|
21 March 25 |
Cambium Bio - Release of Shares from Escrow
×
Cambium Bio - Release of Shares from Escrow |
|
18 March 25 |
Notice of change of interests of substantial holder-CMB
×
Notice of change of interests of substantial holder-CMB |
|
18 March 25 |
FDA Approves Cambium Bio's Potency Assay Strategy for Elate
×
FDA Approves Cambium Bio's Potency Assay Strategy for Elate |
|
12 March 25 |
Notification regarding unquoted securities - CMB
×
Notification regarding unquoted securities - CMB |
|
12 March 25 |
Application for quotation of securities - CMB
×
Application for quotation of securities - CMB |
|
12 March 25 |
Change of Directors Interest Notice
×
Change of Directors Interest Notice |
Load More
Load Less
Ex Dividend Date (est.)
DIV Yield
Franking Level
DPSg
Quality Yield
Falling Divs over next 2
Consensus Score
Recommendation
EPS 1 month Change
Quality Yield
Falling Divs over next 2
Percent of Issue
Value ($M)
Prior Change
7 Day Change
1 Month Change
3 Month Change
Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.
Unlock true investor intelligence
Research, trade and manage global markets from one place with HALO Global. It’s trading - the way you want it.
.svg)
Get the latest insights and hot tips delivered right to your inbox
HALO Technologies Pty Ltd ABN 54 623 830 866 is a Corporate Authorised Representative No 1261916 of Macrovue Pty Ltd ABN 98 600 022 679 AFSL 484264. Macrovue Pty Ltd is a wholly owned subsidiary of HALO Technologies Pty Ltd.
